Suppression of phosphodiesterase IV enzyme by Roflumilast ameliorates cognitive dysfunction in aged rats after sevoflurane anesthesia via PKA‐CREB and MEK/ERK pathways

Peirong Liu,Juan Wang,Sheng Peng,Dan Zhang,Lin Zhuang,Chunliang Liu,Yu Zhang,Xiaowei Shi
DOI: https://doi.org/10.1111/ejn.15751
IF: 3.698
2022-06-30
European Journal of Neuroscience
Abstract:Postoperative cognitive dysfunction (POCD) is a prevalent disorder after anesthesia in the elderly patients. Roflumilast (RF), a phosphodiesterase 4 (PDE‐4) inhibitor, could improve cognition with no side effects. Here, we sought to explore the efficacy of RF in the improvement of cognitive dysfunction caused by sevoflurane (Sev). Sprague‐Dawley rats were anesthetized and the hippocampal neurons were treated with Sev to develop in vivo and in vitro POCD models, followed by RF administration. The mechanism of the PKA‐CREB and MEK/ERK pathways in the pathogenesis of POCD were explored. Sev impaired the cognitive functions of rats, significantly reduced cyclic adenosine monophosphate (cAMP) concentrations and blocked the PKA‐CREB and MEK/ERK pathways. Moreover, the Sev‐treated rats and neurons exhibited enhanced apoptosis and reactive oxygen species (ROS). After treatment with RF, rats had better learning and memory function, and the activity of neurons in hippocampus and cortex was improved. Loss‐of‐function assay indicated that PKA‐CREB and MEK/ERK signaling impairment reduced cAMP levels and promoted apoptosis and ROS in rat hippocampus and neurons. Generally, RF promotes neuronal activity in rats after Sev treatment by maintaining cAMP levels and sustaining the activation of PKA‐CREB and MEK/ERK pathways. This might offer novel sights for POCD therapy.
neurosciences
What problem does this paper attempt to address?